Manufacturer coupons and patient assistance programs cannot be applied to GLP-1 bridge claims
If clinical suspicion exists based on history or examination findings, appropriate evaluationpotentially including thyroid ultrasound, serum calcitonin, or genetic testing for RET mutationsshould be completed before starting therapy
The peptide does not suddenly become inert at day 29, but degradation is a gradual process, and the 28-day guideline provides a reasonable margin of safety
They are best equipped to weigh the potential benefits against the risks, considering an individuals complete medical history, existing conditions, and other medications
Understanding the dosing schedule is fundamental
A complete picture of a studys findings can be difficult to piece together from a press release, says Andres Acosta, a gastroenterologist at the Mayo Clinic in Rochester, Minn